U.S. Entertainment Stock News

Some investors may be wondering whether AXT’s recent share price action still leaves room for value, or if the easy part of the move is already behind it. AXT last closed at US$108.42, with returns of 36.9% over 7 days, 138.5% over 30 days, very large gains year to date of 546.9% and roughly 82x over the past year. These moves can change how the market is viewing both its potential and its risks. Recent coverage has focused on AXT’s position in the semiconductor space and how investor...

Context on Qiagen’s recent share performance Qiagen (QGEN) has drawn attention after a run of weaker returns, with the stock down about 3% over the past week, 16% over the past month, and 34% over the past 3 months. See our latest analysis for Qiagen. Qiagen’s share price has lost momentum over 2024, with the recent 16.5% 1 month share price return and 34.2% 3 month share price return both negative, contributing to a 20.2% negative 1 year total shareholder return. If Qiagen’s recent pullback...

In late April and early May 2026, Seagate Technology Holdings reported sharply higher quarterly and nine‑month earnings, issued fourth‑quarter revenue guidance of about US$3.45 billion, affirmed a US$0.74 per‑share dividend, continued share repurchases under its long‑running buyback, and announced that long‑serving Lead Independent Director Mike Cannon will retire from the Board in October 2026. These developments highlight how Seagate is pairing AI‑driven growth in data‑center storage with...

Recent stock move and business snapshot Butterfly Network (BFLY) stock has recently traded around $4.24, with performance data showing mixed short term moves alongside a stronger past 3 months and 1 year. This has drawn attention to its handheld ultrasound business model. See our latest analysis for Butterfly Network. Recent trading has been volatile, with a 1 day share price return of 6.8% decline and a 7 day share price return of 11.5% decline. However, the 90 day share price return of...

Wondering whether Cushman & Wakefield's current share price reflects its true worth, or if the stock could be mispriced in the market right now? The stock recently closed at US$13.85, with a 1 year return of 35.3%, a 3 year return of 78.5%, a 5 year return of 25.6% decline, a 30 day return of 9.1% and a 7 day return of 1.4% decline. Recent coverage has focused on Cushman & Wakefield as part of the US real estate sector, with attention on how listed property related stocks are pricing in...

In late April 2026, CVR Energy, Inc. reported first quarter 2026 results showing sales of US$1,980 million, a larger net loss of US$192 million, higher refining throughput, a US$0.10 per share cash dividend, and new production guidance for the second quarter. This combination of stronger volumes but wider losses, alongside the decision to pay a dividend, gives investors fresh insight into the company’s balance between growth, profitability, and cash returns. We’ll now examine how higher...

In April 2026, Impinj, Inc. reported first-quarter 2026 results showing essentially flat sales at US$74.25 million year over year, alongside a wider net loss of US$25.26 million and basic and diluted loss per share of US$0.83. At the same time, the company issued second-quarter 2026 guidance that, if achieved, would represent a shift from loss to positive GAAP net income and diluted earnings per share. We’ll now examine how Impinj’s move from a first-quarter loss to guided second-quarter...

Strategy (MSTR) has put a new option on the table, saying it may sell a portion of its large Bitcoin holdings to help fund preferred dividends after reporting a sizeable Q1 net loss. See our latest analysis for Strategy. The news about possible Bitcoin sales comes after a sharp run in the stock, with a 30 day share price return of 45.36% and a 90 day share price return of 33.28%, even though the 1 year total shareholder return is a loss of 56.60% and the 3 year total shareholder return is...

Douglas Emmett (DEI) recently posted first quarter 2026 results that combined a small net loss with stronger funds from operations, record leasing volumes and expanding medical office exposure, giving investors fresh data on the stock. See our latest analysis for Douglas Emmett. The stock has reacted to the Q1 2026 earnings beat on funds from operations and record leasing activity with a 26.37% 1 month share price return. However, the 1 year total shareholder return of 11.62% decline and 5...

Recent performance snapshot for Louisiana-Pacific Louisiana-Pacific (LPX) has drawn investor attention after recent share price moves, with the stock up about 8% over the past month but showing a decline over the past 3 months and year. At a last close of US$75.49 and a market value of roughly US$5.1b, the company sits between shorter term gains and weaker longer term returns. This has prompted a closer look at its current fundamentals. See our latest analysis for Louisiana-Pacific. The...

McKesson (MCK) is back on watch after fourth quarter and full year results showed earnings per share above analyst expectations, a revenue shortfall versus estimates, higher buyback authorization, and upbeat FY2027 guidance. See our latest analysis for McKesson. At a share price of $754.76, McKesson’s recent 30 day share price return of 11.89% and 90 day share price return of 20.44% point to fading short term momentum, while the 1 year total shareholder return of 9.78% and very large 5 year...

In late April 2026, Associated Banc-Corp’s board authorized a new common stock repurchase program of up to US$100 million, reaffirmed regular quarterly dividends on both common and preferred shares, and enacted board changes including the retirement of three directors and the creation of a Technology Committee overseeing data, IT, and cyber risk. This combination of refreshed governance, continued capital return through dividends and buybacks, and an added focus on technology and risk...

WESCO International, Inc. reported past first-quarter 2026 results, with sales rising to US$6,080.1 million and net income reaching US$153.8 million, both higher than a year earlier. The company’s basic earnings per share from continuing operations increased to US$3.16, highlighting improved profitability relative to the prior-year period. We will now examine how this earnings-driven improvement in profitability shapes WESCO International’s broader investment narrative for...

Hut 8 (HUT) is back in focus after signing a 15 year, US$9.8b lease for 352 MW of IT capacity at its Beacon Point AI campus in Texas, expanding its contracted AI infrastructure footprint. See our latest analysis for Hut 8. Hut 8’s latest Beacon Point lease comes after a sharp move in the stock, with a 30 day share price return of 92.14% and a 1 year total shareholder return that is very large, alongside headlines around widening quarterly losses and a pivot toward AI infrastructure...

In early May 2026, Northern Trust supported the launch of the Calamos Autocallable Income UCITS ETF on Waystone’s Irish-domiciled multi-manager platform, the first autocallable ETF in Europe, providing fund administration, depositary, and custody services for its listings on Xetra and the London Stock Exchange. This move highlights Northern Trust’s role in enabling complex, derivatives-based ETF structures for global managers, potentially reinforcing its position in higher-value asset...

Ingredion (INGR) has come under closer investor scrutiny after first quarter 2026 earnings and operating profit declined year over year, which prompted a lower full-year earnings outlook and highlighted operational issues at its Argo facility. See our latest analysis for Ingredion. The weaker first quarter earnings, lower full year guidance and Argo and Cabo plant issues have coincided with a 30 day share price return of a 5.27% decline and a 1 year total shareholder return of a 19.59% loss...

Why Krystal Biotech’s latest earnings are moving the stock Krystal Biotech (KRYS) is back on investors’ radar after Q1 2026 earnings topped expectations, with Vyjuvek-driven revenue and recent FDA approval updates drawing fresh attention to the stock’s risk reward profile. See our latest analysis for Krystal Biotech. Beyond the earnings beat, Krystal Biotech’s share price has picked up momentum, with a 7 day share price return of 13.13% and a year to date share price return of 20.17%, while...

First Financial Bancorp (FFBC) is back in focus after reporting stronger Q1 2026 results, supported by higher net interest income, loan sale gains, and contributions from its recent Westfield and BankFinancial acquisitions. See our latest analysis for First Financial Bancorp. At a share price of $30.43, First Financial Bancorp has a 30.36% 1 year total shareholder return. The 3 year total shareholder return of 88.45% signals stronger longer term momentum than the recent 7% 1 month share price...

If you are wondering whether Quest Diagnostics at around US$190.84 per share offers good value today, it helps to step back and look at the stock through a few different valuation lenses. The share price has seen mixed recent returns, with a 1.7% decline over 7 days and a 3.0% decline over 30 days, set against a 9.8% gain year to date and 10.4% over the past year, plus longer term returns of 54.8% over 3 years and 53.1% over 5 years. Recent coverage has focused on Quest Diagnostics as a US...

Why TETRA Technologies Stock Is On Investors’ Radar TETRA Technologies (TTI) has drawn interest after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months. This has prompted investors to reassess its current valuation and business profile. See our latest analysis for TETRA Technologies. At a share price of US$9.77, TETRA Technologies has seen a 19.9% 1 month share price return but a 16.3% 3 month share price decline, while the 1 year...

RAPP shares react to RAP-219 trial update and new China partnership Rapport Therapeutics (RAPP) has drawn fresh attention after reporting encouraging follow-up data from its Phase 2a RAP-219 trial in focal onset seizures, accelerating Phase 3 timelines and signing a partnership with Tenacia Biotechnology for Greater China rights. See our latest analysis for Rapport Therapeutics. The recent Phase 2a RAP-219 update and China licensing deal come on top of first quarter results that showed a net...

If you are wondering whether Capital Southwest stock still offers value at its current price, this article walks through the numbers so you can judge how the valuation stacks up for yourself. With the share price at US$23.99, recent returns of 6.3% over 30 days, 7.6% year to date and 35.5% over the past year put a clear spotlight on how investors are currently pricing the stock and what that might mean for future risk and reward. Those returns sit alongside a longer record, including 89.7%...

ITT’s latest earnings jolt investor attention ITT (ITT) drew fresh interest after its Q1 2026 results, where revenue and adjusted earnings topped consensus forecasts, helped by strong organic sales and the integration of SPX FLOW operations. See our latest analysis for ITT. Despite a 4.1% one day share price pullback after the results and a softer 7 day share price return, ITT’s 19.3% year to date share price return and very strong multi year total shareholder returns suggest that momentum...

Atlassian (TEAM) has put AI at the center of its story, with the newly opened Teamwork Graph and expanded Rovo agents turning years of product work into a clearer thesis for the stock. See our latest analysis for Atlassian. That AI push is arriving after a sharp rebound in momentum, with a 7 day share price return of 34.67% and 30 day share price return of 42.48%. This comes even though the year to date share price return is a 40.31% decline and the 1 year total shareholder return is a 55.64%...